Scurvy on the rise in the United States: Pediatric cases triple in five years

The FDA on Wednes­day ap­proved Basilea’s an­tibi­ot­ic Zevtera to treat three con­di­tions: staph in­fec­tions, acute bac­te­r­i­al skin and skin struc­ture in­fec­tions, and com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia.

Pfiz­er ter­mi­nat­ed one of two late-stage tri­als for a sick­le cell treat­ment can­di­date from its $5.4 bil­lion ac­qui­si­tion of Glob­al Blood Ther­a­peu­tics in 2022. The